Mauro D'Amato1. 1. Department of Biosciences and Nutrition, Karolinska Institutet, Stockholm, Sweden. mauro.damato@ki.se
Abstract
BACKGROUND: The functional gastrointestinal disorders (FGID), and in particular irritable bowel syndrome (IBS), pose a considerable burden on health care and society, and negatively impact quality of life. These are common conditions of unknown etiology, and symptom-based criteria are currently the sole nosological tools for their clinical classification. Major insight into FGID pathophysiology is therefore needed and, in recent years, increasing hope has been put on genetic research for the identification of causative pathways. This is more advanced in IBS compared with other FGID, but it has still provided often indecipherable results and no unequivocal evidence of a pathogenetic role for any particular gene. Although thousands of genetic variants have been undoubtedly linked to human disease in hundreds of genome-wide association studies (GWAS), no similar effort has yet even been attempted in FGID. If meaningful, robust, and reproducible results are to be obtained for IBS and other FGID, we must shift gear and adopt these powerful hypothesis-free approaches through concerted actions and allocation of adequate resources. Provided these are in place, the major challenge will be, inevitably, the choice of the target phenotype(s) beyond a descriptive symptom-based classification. PURPOSE: In view of these much awaited developments, salient results and difficulties inherent to IBS gene discovery are briefly summarized here.
BACKGROUND: The functional gastrointestinal disorders (FGID), and in particular irritable bowel syndrome (IBS), pose a considerable burden on health care and society, and negatively impact quality of life. These are common conditions of unknown etiology, and symptom-based criteria are currently the sole nosological tools for their clinical classification. Major insight into FGID pathophysiology is therefore needed and, in recent years, increasing hope has been put on genetic research for the identification of causative pathways. This is more advanced in IBS compared with other FGID, but it has still provided often indecipherable results and no unequivocal evidence of a pathogenetic role for any particular gene. Although thousands of genetic variants have been undoubtedly linked to human disease in hundreds of genome-wide association studies (GWAS), no similar effort has yet even been attempted in FGID. If meaningful, robust, and reproducible results are to be obtained for IBS and other FGID, we must shift gear and adopt these powerful hypothesis-free approaches through concerted actions and allocation of adequate resources. Provided these are in place, the major challenge will be, inevitably, the choice of the target phenotype(s) beyond a descriptive symptom-based classification. PURPOSE: In view of these much awaited developments, salient results and difficulties inherent to IBS gene discovery are briefly summarized here.
Authors: Lesha Pretorius; Anton du Preez Van Staden; Johannes J Van der Merwe; Natasha Henning; Carine Smith Journal: Inflammopharmacology Date: 2022-01-13 Impact factor: 4.473
Authors: Peter R Strege; Amelia Mazzone; Cheryl E Bernard; Leila Neshatian; Simon J Gibbons; Yuri A Saito; David J Tester; Melissa L Calvert; Emeran A Mayer; Lin Chang; Michael J Ackerman; Arthur Beyder; Gianrico Farrugia Journal: Am J Physiol Gastrointest Liver Physiol Date: 2017-11-22 Impact factor: 4.052
Authors: Ferdinando Bonfiglio; Tenghao Zheng; Koldo Garcia-Etxebarria; Fatemeh Hadizadeh; Luis Bujanda; Francesca Bresso; Lars Agreus; Anna Andreasson; Aldona Dlugosz; Greger Lindberg; Peter T Schmidt; Pontus Karling; Bodil Ohlsson; Magnus Simren; Susanna Walter; Gerardo Nardone; Rosario Cuomo; Paolo Usai-Satta; Francesca Galeazzi; Matteo Neri; Piero Portincasa; Massimo Bellini; Giovanni Barbara; Anna Latiano; Matthias Hübenthal; Vincent Thijs; Mihai G Netea; Daisy Jonkers; Lin Chang; Emeran A Mayer; Mira M Wouters; Guy Boeckxstaens; Michael Camilleri; Andre Franke; Alexandra Zhernakova; Mauro D'Amato Journal: Gastroenterology Date: 2018-04-05 Impact factor: 22.682